Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Assets Average (2016 - 2025)

Historic Assets Average for Neurocrine Biosciences (NBIX) over the last 14 years, with Q4 2025 value amounting to $4.4 billion.

  • Neurocrine Biosciences' Assets Average rose 2265.74% to $4.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.4 billion, marking a year-over-year increase of 2265.74%. This contributed to the annual value of $4.2 billion for FY2025, which is 1980.03% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Assets Average stood at $4.4 billion for Q4 2025, which was up 2265.74% from $4.1 billion recorded in Q3 2025.
  • Neurocrine Biosciences' 5-year Assets Average high stood at $4.4 billion for Q4 2025, and its period low was $1.8 billion during Q1 2021.
  • Over the past 4 years, Neurocrine Biosciences' median Assets Average value was $3.4 billion (recorded in 2024), while the average stood at $3.1 billion.
  • In the last 5 years, Neurocrine Biosciences' Assets Average surged by 5361.31% in 2024 and then surged by 1015.2% in 2025.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Assets Average stood at $2.0 billion in 2021, then surged by 53.5% to $3.0 billion in 2023, then grew by 18.92% to $3.6 billion in 2024, then increased by 22.66% to $4.4 billion in 2025.
  • Its last three reported values are $4.4 billion in Q4 2025, $4.1 billion for Q3 2025, and $3.8 billion during Q2 2025.